Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not

Wenjia Chen, Mohsen Sadatsafavi, Lakmini Bulathsinhala, Esther Garcia Gil, Trung Tran, J. Mark Fitzgerald, Ruth Murray, David Price, Isar Glitter Working Group
European Respiratory Journal 2021 58: PA1105; DOI: 10.1183/13993003.congress-2021.PA1105
Wenjia Chen
1Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: chwenjia@gmail.com
Mohsen Sadatsafavi
2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lakmini Bulathsinhala
3Observational and Pragmatic Research Institute, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
4AstraZeneca, Gaithersburg, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trung Tran
4AstraZeneca, Gaithersburg, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Mark Fitzgerald
5Centre for Lung Health, Vancouver, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Murray
3Observational and Pragmatic Research Institute, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Price
3Observational and Pragmatic Research Institute, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isar Glitter Working Group
3Observational and Pragmatic Research Institute, Singapore, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

Introduction: Information on characteristics of severe asthma patients with high oral corticosteroid exposure (HOCS) initiating biologics is limited.

Aim: To compare characteristics of severe asthma patients with HOCS based on biologic initiation.

Methods: Profiles of patients with HOCS (≥1-year long-term OCS therapy, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR), who initiated or did not initiate biologics (anti-lgE, anti-IL5/anti-IL5R or anti-IL4R) were compared at biologic initiation or registry enrolment.

Results: Between May 2015 and January 2021, 13.3% (1412) of 10606 patients from 19 countries had HOCS. Of whom, 996 initiated biologics and 416 did not. Patients initiating biologics were more likely to be male, White, eosinophilic (via a new Eosinophilic Phenotype Classification; Perez-de-Llano L, et al. AJRCCM 2020;201: A4525), had greater airflow limitation (post-bronchodilator FEV1/FVC ratio<0.7), nasal polyps, positive serum allergen tests and uncontrolled asthma (Figure). Biologic initiators were younger at baseline (51.6 vs. 53.2 years) but both groups had similar annual asthma exacerbations rates (5.7 vs 5.3, p=0.14).

Conclusions: HOCS patients have different baseline characteristics based on biologic initiation. Future biologic comparative effectiveness research should account for these differences.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

  • Severe asthma
  • Chronic diseases
  • Asthma - management

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1105.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
Wenjia Chen, Mohsen Sadatsafavi, Lakmini Bulathsinhala, Esther Garcia Gil, Trung Tran, J. Mark Fitzgerald, Ruth Murray, David Price, Isar Glitter Working Group
European Respiratory Journal Sep 2021, 58 (suppl 65) PA1105; DOI: 10.1183/13993003.congress-2021.PA1105

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
Wenjia Chen, Mohsen Sadatsafavi, Lakmini Bulathsinhala, Esther Garcia Gil, Trung Tran, J. Mark Fitzgerald, Ruth Murray, David Price, Isar Glitter Working Group
European Respiratory Journal Sep 2021, 58 (suppl 65) PA1105; DOI: 10.1183/13993003.congress-2021.PA1105
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Implementation of an integrated care model for fragile COPD patients: a controlled prospective study
  • Increased Exacerbations of Chronic Obstructive Pulmonary Disease in Alpha-1 Antitrypsin Carriers
  • LSC - 2021 - Effects of mild to moderate asthma in pregnancy on the wellbeing of mother and newborn; A case control study from Sri Lanka
Show more Monitoring airway disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society